Via its US subsidiary Takeda America Holdings, Takeda Pharmaceutical has moved to strengthen its oncology pipeline by agreeing to acquire Intellikine for up to US$310 M, including US$190 M in cash upfront and up to US$120 M in potential clinical development milestone payments. With the acquisition, Takeda will gain Intellikine’s portfolio of selective small molecule kinase inhibitors that target specific isoforms of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).